The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation.

[1]  R. Decker,et al.  A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma , 2017, JAMA oncology.

[2]  N. Dunlap,et al.  Distribution of Cervical Lymph Node Metastases From Squamous Cell Carcinoma of the Oropharynx in the Era of Risk Stratification Using Human Papillomavirus and Smoking Status. , 2015, International journal of radiation oncology, biology, physics.

[3]  R. Gandour-Edwards,et al.  Level IB nodal involvement in oropharyngeal carcinoma: Implications for submandibular gland‐sparing intensity‐modulated radiotherapy , 2015, The Laryngoscope.

[4]  K. Ang,et al.  Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Garden,et al.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Sormani,et al.  HPV-related oropharyngeal carcinoma with Overt Level II and/or III metastases at presentation: The risk of subclinical disease in ipsilateral levels IB, IV and V , 2014, Acta oncologica.

[7]  A. Psyrri,et al.  Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Wei Xu,et al.  Temporal nodal regression and regional control after primary radiation therapy for N2-N3 head-and-neck cancer stratified by HPV status. , 2013, International journal of radiation oncology, biology, physics.

[9]  R. Mehra,et al.  Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns , 2013, Head & neck.

[10]  L. Specht,et al.  The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  N J Sarlis,et al.  Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  R. Tishler,et al.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. , 2011, The Lancet. Oncology.

[13]  Emma Hall,et al.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial , 2011, The Lancet. Oncology.

[14]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[16]  M. Sormani,et al.  Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma. , 2008, International journal of radiation oncology, biology, physics.

[17]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.